NASDAQ: PROKProkidney Corp Stock
$1.64-0.02 (-1.2%)
Updated Jun 12, 2026
PROK Price
$1.64
Fair Value Price
$0.76
Market Cap
$495.38M
52 Week Low
$0.54
52 Week High
$7.13
P/E
-3.09x
P/B
-0.48x
P/S
285.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$889.00k
Earnings
-$72.29M
Gross Margin
100%
Operating Margin
-8,149.27%
Profit Margin
-8,131.5%
Debt to Equity
-0.03
Operating Cash Flow
-$132M
Beta
1.34
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PROK Overview
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PROK's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PROK
Ranked#432 of 463
Ranked#432 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important PROK news, forecast changes, insider trades & much more!
PROK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PROK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PROK ($1.64) is overvalued by 117.07% relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PROK ($1.64) is not significantly undervalued (117.07%) relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PROK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PROK due diligence checks available for Premium users.
Valuation
PROK fair value
Fair Value of PROK stock based on Discounted Cash Flow (DCF)
Price
$1.64
Fair Value
$0.76
Overvalued by
117.07%
PROK ($1.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PROK ($1.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PROK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PROK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.09x
Industry
16.53x
Market
14.15x
PROK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.48x
Industry
4.85x
PROK's financial health
Profit margin
Revenue
$226.0k
Net Income
-$20.0M
Profit Margin
-8,865.9%
PROK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PROK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$292.8M
Liabilities
$29.7M
Debt to equity
-0.03
PROK's short-term assets ($234.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PROK's short-term assets ($234.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PROK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PROK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.7M
Investing
$34.8M
Financing
$215.0k
PROK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PROK vs Biotech Stocks
Prokidney Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.